We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+29.79%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$474M
AUM Growth
+$47.9M
Cap. Flow
-$48.4M
Cap. Flow %
-10.21%
Top 10 Hldgs %
33.88%
Holding
142
New
32
Increased
21
Reduced
37
Closed
28

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$23.6M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$13.1M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$7.57M
4
CLBT icon
Cellebrite
CLBT
+$4.7M
5
VRNS icon
Varonis Systems
VRNS
+$4.1M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.5M
2
NVMI
Nova
NVMI
+$8.82M
3
NVDA icon
NVIDIA
NVDA
+$8.61M
4
CYTK icon
Cytokinetics
CYTK
+$6.81M
5
TVTX icon
Travere Therapeutics
TVTX
+$6.3M

Sector Composition

Rank Sector Weight
1 Healthcare 64.08%
2 Technology 17.97%
3 Industrials 0.72%
4 Consumer Discretionary 0.64%
5 Communication Services 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$37.3B
$30.4M 6.42%
1,507,025
-113,965
-7% -$2M
NICE icon
2
Nice
NICE
$5.87B
$22.8M 4.81%
+157,400
New +$23.6M
TSEM icon
3
Tower Semiconductor
TSEM
$26.5B
$22.5M 4.76%
311,802
+47,080
+18% +$2.57M
MRUS
4
CALL
DELISTED
Merus
MRUS
$14.1M 2.98%
+150,000
New +$9.77M
NVMI
5
Nova
NVMI
$13.9B
$14M 2.96%
43,896
-31,940
-42% -$8.82M
QQQ icon
6
Invesco QQQ Trust
QQQ
$466B
$13.8M 2.91%
+22,960
New +$13.1M
BIIB icon
7
Biogen
BIIB
$30.4B
$11.6M 2.44%
82,738
– –
RARE icon
8
Ultragenyx Pharmaceutical
RARE
$2.88B
$10.6M 2.24%
352,558
+252,473
+252% +$7.57M
AZN icon
9
AstraZeneca
AZN
$262B
$10.4M 2.19%
67,530
– –
SNY icon
10
Sanofi
SNY
$107B
$10.4M 2.19%
219,515
– –
CDTX
11
CALL
DELISTED
Cidara Therapeutics
CDTX
$9.58M 2.02%
+100,000
New +$6.38M
CYTK icon
12
Cytokinetics
CYTK
$10.9B
$8.88M 1.87%
161,517
-165,201
-51% -$6.81M
MLYS icon
13
Mineralys Therapeutics
MLYS
$2.39B
$8.34M 1.76%
219,910
-261,064
-54% -$5.65M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$7.81M 1.65%
991,142
+424
+0% +$3.02K
LLY icon
15
Eli Lilly
LLY
$1.05T
$7.66M 1.62%
10,040
-1,500
-13% -$1.12M
JNJ icon
16
Johnson & Johnson
JNJ
$609B
$7.57M 1.6%
40,831
– –
CDTX
17
DELISTED
Cidara Therapeutics
CDTX
$7.25M 1.53%
75,743
-62,258
-45% -$3.97M
FBRX icon
18
Forte Biosciences
FBRX
$1B
$7.11M 1.5%
474,309
-20,800
-4% -$240K
BBIO icon
19
CALL
BridgeBio Pharma
BBIO
$15.9B
$6.75M 1.42%
+130,000
New +$6.34M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$2.02B
$5.97M 1.26%
387,716
-1,183,848
-75% -$15.5M
TRVI icon
21
Trevi Therapeutics
TRVI
$2.71B
$5.89M 1.24%
643,957
-156,000
-20% -$1.17M
NVO
22
Novo Nordisk
NVO
$223B
$5.86M 1.24%
105,677
– –
ABBV icon
23
AbbVie
ABBV
$450B
$5.85M 1.23%
25,256
– –
CLBT icon
24
Cellebrite
CLBT
$3.85B
$5.54M 1.17%
+298,948
New +$4.7M
ANNX icon
25
Annexon
ANNX
$950M
$5.47M 1.15%
1,794,387
+30,000
+2% +$74.5K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
SCM
Schnieders Capital Management Pasadena, California $629M AUM 28.1% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
WAAG
Wealth Alliance Advisory Group Wichita, Kansas $632M AUM 18.54% 1-Year Est. Return

Sphera Funds Management's Q3 2025 Portfolio in Review

As of Q3 2025, Sphera Funds Management held 142 positions worth $474M, up 11% from $426M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management withdrew a net $48.4M in Q3 2025, closing 28 positions and reducing 37 holdings. Its most notable exit was NVIDIA, an estimated $8.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Nice worth $22.8M.

  • Sphera Funds Management's largest Q3 2025 buy was Nice: 157,400 shares worth $22.8M.
  • Sphera Funds Management added most to Ultragenyx Pharmaceutical in Q3 2025, an estimated $7.57M increase.
  • Sphera Funds Management's biggest Q3 2025 reduction was Syndax Pharmaceuticals, cutting an estimated $15.5M.
  • Sphera Funds Management fully exited NVIDIA in Q3 2025, selling an estimated $8.61M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $474M portfolio in Q3 2025.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2025.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $474M.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.